Cancer therapy: Switching off oncogenes

BioEssays

Volumn 25, Issue 2, 2003, Pages 104-107

  Pompetti, Franca ^a   Pilla, Daniela ^a   Giancola, Raffaella ^a  

^a Civil Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; BIOACCUMULATION; CANCER THERAPY; CELL CLONE; CELL PROLIFERATION; DOWN REGULATION; HUMAN; ONCOGENE; ONCOGENE MYC; OSTEOCYTE; OSTEOSARCOMA; PHENOTYPE; REGRESSION ANALYSIS; REVIEW; TUMOR CELL;

ANIMALS; BONE NEOPLASMS; DOWN-REGULATION; GENES, MYC; HUMANS; MICE; NEOPLASMS; ONCOGENES; OSTEOSARCOMA;

EID: 0037321689     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.10238     Document Type: Review

References (26)

1. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM, Felsher DW. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002;297:102-104.
2. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001;411:342-348.
3. Volgestein B. Many genes changes found in cancer. Science 1989;246:1386-1388.
4. Parada LP, Tabin CJ, Shih C, Weimberg RA. Human EJ bladder carcinoma is a homologue of Harvey sarcoma ras gene. Nature 1982;297:474-477.
5. Ponder BAJ. Cancer genetics. Nature 2001;411:336-341.
6. Kinsler KW, Volgestein B. Gatekeepers and caretakers. Nature 1997;386:761-764.
7. Evan GI, Wyllie AH, Gilbert GS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992;69:119-129.
8. Fest T, Mougey V, Dalstein V, Hagerty M, Milette D, Silva S, Mai S. C-myc overexpression in Ba/F3 cells simultaneously elicits genomic instability and apoptosis. Oncogenes 2002;21:2981-2990.
9. Felsher DW, Bischop JM. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. PNAS 1999;96:3940-3944.
10. Sheen JH, Dickson RB. Overexpression of c-myc alters G1/S arrest following ionizing radiation. Molecular Cell Biology 2002;22:1819-1833.
11. Felsher DW, Zettemberg A, Zhu J, Tisty T, Bishop JM. Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. PNAS 2000;97:10544-10548.
12. Field JK, Spandidos DA. The role of the myc and ras oncogenes in human solid tumours and their relevance in diagnosis and prognosis. Anticancer Res 1990;10:1-22
13. Pelengaris S, Littlewood T, Khan M, Ella G, Evan G. Reversible activation of c-myc in skin induction of a complex neoplastic phenotype by a single oncogenic lesion. Molec Cell 1999;3:565-577.
14. Pompetti F, Rizzo P, Simon RM, Freidlin B, Mew DJ, Pass HI, Picci P, Levine AS, Carbone M Oncogene alterations in primary, recurrent and metastatic human bone tumors. J Cell Biochem 1996;63:37-50.
15. Gamberi G, et al. C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression. Oncology 1998;55:556-563.
16. Gibbs JB. Mechanism-based target identification and drug discovery in cancer research. Science 2000;287:1969-1973.
17. Felsher DW, Bishop JM. Reversible tumorigenesis by myc in hematopoietic lineages. Molecular Cell 1999;4:199-207.
18. Sturm SA, Strauss PG, Adolph S, Hameister H, Erfle V. Amplification and rearrangement of c-myc in radiation-induced murine osteosarcomas. Cancer Res 1990;50:4146-4153
19. Huettner CS, Zhang P, Van Etten RA, Tenen DG. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nature Genet 2000;24:57-60
20. Bailin SB, Herman JG. DNA methilation in tumorigenesis. Trends Genet 2000;16:168-174
21. Druker JB, et al. Efficacy and safety of a specific inhibitor of the BCR/ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
22. Druker JB, Sawyers CL, Kantarjiain H, Resta DJ, Fernandez Reese S, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR/ABL tyrosine kinase in the blast crisis of chronic myeolid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042.
23. Deinninger MW, Goldman MJ, Lydon M, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibit the growth of BCR/ABL positive cells. Blood 1997;90:3691-3698.
24. Kelly LM, et al. CT 53518 a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cells 2002;1:421-432.
25. O'Farrell AM, Abrams T, Yueng H, Ngai T, Louie S, Wong L, Heinrich M, Yee M, Smolich B, Murray L. SUGEN Compounds SU5416 and SU11248 inhibit FLT3 activity: therapeutic applications in AML. Blood 2001;96:2434-2443.
26. Herbst RS, Hidalgo M, Pierson AS, Holden SN, Bergen M, Eckhardt SG. Angiogenesis inhibitors in clinical development for lung cancer. Semin Oncol 2002;29:66-77.